Showing 2981-2990 of 5621 results for "".
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Vision Expo East Announces Keynote Speakerhttps://modernod.com/news/vision-expo-east-announces-keynote-speaker/2481419/Vision Expo East announced that Jason Romero, a legally blind ultra-runner, will be the keynote speaker at the annual conference in New York City from March 16-19, 2023 (Education opens March 16; Exhibits open March 17). “After losing his vision to a dege
- IOT Introduces Neochromes Agile Dark Lenseshttps://modernod.com/news/iot-introduces-neochromes-agile-dark-lenses/2481397/Spain-based IOT has introduced Neochromes Agile Dark light activated lenses. Featuring exclusive dyes from IOT, the latest agile dark lenses are darker than the company's current Neochromes, yet are designed to fade back just as quickly, according to IOT. Th
- Research Challenges “Sugar Hypothesis” of Diabetic Cataract Developmenthttps://modernod.com/news/research-challenges-sugar-hypothesis-of-diabetic-cataract-development/2481371/New findings from investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, contradict previous notions about sugar’s role i
- CORE Names Its “Top 10 of 2022” Scientific Papershttps://modernod.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/Ahead of the first global eye care conference of the year, the Centre for Ocular Research & Education (CORE) has announced its “Top 10 of 2022” publications list, designating works of significant value to clinicians, researchers, educators, and manufacturers. The papers
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- Conference and Exhibit Hall Registration Now Open for Vision Expo East 2023 Taking Place March 16-19 in New York Cityhttps://modernod.com/news/conference-and-exhibit-hall-registration-now-open-for-vision-expo-east-2023-taking-place-march-16-19-in-new-york-city/2481282/Conference and Exhibit Hall Registration opens today for
- NeoLight Launches ROP Risk Management Software ROPCheck.comhttps://modernod.com/news/neolight-launches-rop-risk-management-software-ropcheckcom/2481271/NeoLight announced that it is releasing ROP Check, a software used in digital care coordination for pediatric retinal screening to detect and monitor progression of retinopathy of prematurity (ROP). The launch comes 1 year after NeoLight acquired Phoenix Technology Group, which bro
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the